The research agreement
Lunit Inc. and Summit Therapeutics Inc. said in the announcement that they have entered a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab. Lunit is listed on the Korea Exchange under 328130; Summit trades on Nasdaq under SMMT.
What the analysis covers
The work will apply SCOPE IO to hematoxylin and eosin-stained whole-slide images to characterize tumor microenvironment features. The companies said they aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies. SCOPE IO is designed to support immuno-oncology research and biomarker development, and the companies said it allows assessment of tumor microenvironment features from H&E slides without additional stains or assays.
The drug being studied
Summit is developing ivonescimab, an investigational bispecific antibody intended to combine PD-1 blockade with VEGF blockade in a single molecule, in several solid tumors. According to the announcement, it is not approved by any regulatory authority in Summit's license territories, which include the United States and Europe, and it was first approved for marketing in China in May 2024. The release states that ivonescimab was invented by Akeso Inc.
What the companies say
Allen Yang, Summit's chief research and development strategy officer, said understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations, and that Summit is looking at whether AI-powered pathology can generate deeper, more scalable insight from routine tissue samples. Lunit chief executive Brandon Suh said the platform extracts quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, which the company believes can help biopharma partners understand which patients may benefit from immuno-oncology therapies and why.
Lunit said its SCOPE products are for research use only and not for use in diagnostic procedures or decisions. The companies said no clinical outcome data are being announced.
